Patents by Inventor Nicholas Harris
Nicholas Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230407272Abstract: Provided herein are genetically modified yeast cells that recombinantly express a gene encoding an alcohol-O-acyltransferase (AAT) enzyme and a gene encoding a fatty acid synthase a subunit (FAS2) enzyme. Also provided are methods of producing fermented beverages and compositions comprising ethanol using the genetically modified yeast cells described herein.Type: ApplicationFiled: November 12, 2021Publication date: December 21, 2023Applicant: Berkeley Fermentation Science Inc.Inventors: Rachel Li, Jeremy Roop, Nicholas Harris, Charles Denby
-
Patent number: 11718174Abstract: An all-wheel-drive vehicle includes a primary axle operably coupled to an engine and a secondary axle having an input operably coupled to the engine a first halfshaft, a second halfshaft, a first clutch selectively connecting the first halfshaft to the input, and a second clutch selectively connecting the second halfshaft to the input. A transmission has an input coupled to the engine and output coupled to the primary drive axle. A driveshaft couples a power-transfer unit and the input, and a third clutch selectively couples the output to the driveshaft. A controller is programmed to, during a power-limiting routine, command a torque to the engine based on closed-loop feedback control such that the torque decreases when a calculated slip of a selected one of the first and second clutches is greater than a target slip of the selected clutch and increases when the calculated slip is less than the target slip.Type: GrantFiled: May 25, 2021Date of Patent: August 8, 2023Assignee: Ford Global Technologies, LLCInventors: Nicholas Harris, Andrew Monticello, Kyle Culek, Ashok E. Rodrigues
-
Publication number: 20220379722Abstract: A vehicle includes a powertrain having a powerplant and a clutch that selectively couples the powerplant to an axle. A controller is programmed to, in response to the powertrain being in a power-limiting routine, command a torque to the powerplant based on an error between a target slip of the clutch and a slip of the clutch.Type: ApplicationFiled: May 25, 2021Publication date: December 1, 2022Inventors: Nicholas Harris, Andrew Monticello, Kyle Culek, Ashok E. Rodrigues
-
Patent number: 11207381Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: GrantFiled: February 13, 2018Date of Patent: December 28, 2021Assignee: SYMYTHERA CANADA LTD.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20190022185Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: February 13, 2018Publication date: January 24, 2019Inventors: Chai EZERZER, Nicholas HARRIS
-
Patent number: 9931376Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: GrantFiled: August 15, 2016Date of Patent: April 3, 2018Assignee: SYMTHERA CANADA LTD.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20170168813Abstract: Embodiments provide a library that allows developers to very quickly build and deploy services or resource providers without having to interpret a complex cloud protocol specification. The SDK implements resource storage, automatically handles resource lifecycle, provides appropriate hooks to plug into external systems, facilitates handling of subscription-wide operations, implements complex flows such as moving of resources, enables appropriate security features, and creates necessary endpoints for the developer's service.Type: ApplicationFiled: April 22, 2016Publication date: June 15, 2017Applicant: Microsoft Technology Licensing, LLC.Inventors: Vladimir Pogrebinsky, Nicholas Harris, Shriram Natarajan, Roger Sprague, Florin Bejinaru
-
Publication number: 20160346355Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: August 15, 2016Publication date: December 1, 2016Inventors: Chai Ezerzer, Nicholas Harris
-
Patent number: 9416158Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: GrantFiled: April 21, 2014Date of Patent: August 16, 2016Assignee: SYMTHERA CANADA LTD.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20140378371Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: April 21, 2014Publication date: December 25, 2014Applicant: Symthera Canada Ltd.Inventors: Chai Ezerzer, Nicholas Harris
-
Patent number: 8703911Abstract: The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a G-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: GrantFiled: March 18, 2007Date of Patent: April 22, 2014Assignee: SymThera Canada Ltd.Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20100227824Abstract: The invention provides pharmaceutical compositions comprising at least a portion of a chemokine receptor or a G-protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis, rheumatoid arthritis and asthma. The invention also provides peptides that may be used individually, in combination with, or in combination with other therapeutic agents such as steroid, non-steroid anti-inflammatory drug, immune modulator or immune suppressor.Type: ApplicationFiled: October 9, 2009Publication date: September 9, 2010Inventors: Chai Ezerzer, Nicholas Harris
-
Publication number: 20100034771Abstract: The invention provides a pharmaceutical composition including a cytokine and a peptide comprising at least a portion of a chemokine receptor or a c_protein coupled receptor. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma. The invention also provides peptides that may be used in the pharmaceutical composition and a method for preparing the pharmaceutical composition of the invention. The invention further provides a method for to treating an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, and psoriasis asthma.Type: ApplicationFiled: March 18, 2007Publication date: February 11, 2010Applicant: PROTAGONISTS LTD.Inventors: Chai Ezerzer, Nicholas Harris
-
Patent number: 7365080Abstract: The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.Type: GrantFiled: February 5, 2004Date of Patent: April 29, 2008Assignee: Rimonyx Pharmaceuticals Ltd.Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk
-
Publication number: 20070191400Abstract: The present invention provides pharmaceutical compositions comprising quinazolinecarboxamide derivative, and certain novel quinazolinecarboxamide derivatives capable of inhibiting heparan sulfate-glycosaminoglycan (HS-GAGs) interactions with L-selectin, and useful in the prevention or treatment of various diseases, disorders and conditions mediated by HS-GAGs, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.Type: ApplicationFiled: March 24, 2005Publication date: August 16, 2007Applicant: Rimonyx Pharmaceuticals Ltd.Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk
-
Publication number: 20070179137Abstract: The present invention relates to a method of screening for small organic molecules that directly inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding viral proteins (GBVPs), which comprises contacting a GAG with an GBVP in the presence of at least one candidate compound; and measuring the amount of the GAG bound to the GBVP or the amount of the GBVP bound to the GAG, wherein a significant decrease in GAG-GBVP binding as compared to GAG-GBVP binding in the absence of the candidate compound, identifies said compound as inhibitor of the GAG-GBVP interaction. The invention further provides pharmaceutical compositions comprising certain 2-thioxo-thiazolidinone derivatives, particularly useful against virus infections.Type: ApplicationFiled: March 24, 2005Publication date: August 2, 2007Applicant: RIMONYX PHARMACEUTICALS LTD.Inventors: Paul Gregor, Nicholas Harris, Regina Zhuk
-
Publication number: 20070007827Abstract: An electromagnetic generator comprising a multilayer assembly of a first layer carrying at least one magnet, a second layer carrying at least one coil, and a third layer carrying at least one magnet, the at least one magnet of the first and third layers being configured to define therebetween a region of magnetic flux in which the at least one coil is disposed, at least one of the layers being shaped to define a respective displaceable portion thereof which is displaceable by vibration of the electromagnetic generator thereby to cause relative movement between the coil and the magnets and generate an electrical current in the coil.Type: ApplicationFiled: August 13, 2004Publication date: January 11, 2007Inventors: Nicholas Harris, Michael Tudor, Neil White, Stephen Beeby, Peter Glynne-Jones
-
Publication number: 20060275214Abstract: The present invention relates to methods for screening small organic compounds capable of inhibiting the interactions of glycosaminoglycans with effector cell adhesion molecules. Specifically, the present invention provides a method for screening of small organic compounds, the compounds inhibit the interaction of heparin with L-selectin or P-selectin. The compounds identified by the methods of the invention are useful for treating inflammatory disorders, autoimmune diseases and cancer.Type: ApplicationFiled: December 30, 2003Publication date: December 7, 2006Applicant: Rimonyx Pharmaceuticals LTD.Inventors: Paul Gregor, Nicholas Harris, Juraj Koppel
-
Publication number: 20060135529Abstract: The present invention provides thieno[2,3-C]pyridine derivatives, pharmaceutical compositions comprising the thieno[2,3-C]pyridine derivatives, and methods of use thereof. The compounds capable of inhibiting glycosaminoglycan (GAG) interactions with effector cell adhesion molecules (ECAM) are useful for treating diseases and disorders mediated by GAG-ECAMs interactions, particularly inflammatory and autoimmune diseases, viral diseases, cancer, and amyloid disorders.Type: ApplicationFiled: February 5, 2004Publication date: June 22, 2006Applicant: Rimonyx Pharmaceuticals LtdInventors: Paul Gregor, Nicholas Harris, Juraj Koppel, Regina Zhuk
-
Patent number: D926445Type: GrantFiled: March 17, 2020Date of Patent: August 3, 2021Assignee: LULULEMON ATHLETICA CANADA INC.Inventors: Nichola Harris, Rinske Smith, Monika Marie Rutledge